Skip to main content
. 2018 Mar 20;118(8):1051–1055. doi: 10.1038/s41416-018-0026-9

Fig. 2.

Fig. 2

Progression-free survival (PFS) curves of responders (top curve, > 50% drop in sum of SUVmax and plasma EBV DNA clearance of ≤ 10 days, 1-year PFS rate 86.2%) versus non-responders (bottom curve, ≤ 50% drop in SUVmax and plasma EBV DNA clearance of > 10 days, 1-year PFS 36.5%) based on the dual endpoint (log-rank p = 0.0047)